Iressa Trocaine in the treatment of EGFR-mutated non-small cell lung cancer

Share This Post

Cancer genetic testing

Cancer gene testing guides targeted therapy as the core technology for precise cancer treatment. Every cancer patient should perform cancer gene testing for himself, looking for effective targeted drugs and clinical trials for treatment. The Global Oncologist Network, in conjunction with the US genetic testing agency and the domestic top-notch genetic testing agency, provides patients with accurate cancer genetic testing and expert consultation services to help patients formulate the most accurate treatment plan.

The FDA recently approved Iressa as a single-agent therapy for metastatic non-small cell lung cancer (NSCLC) positive for epidermal growth factor receptor (EGFR) mutations confirmed by an FDA-approved companion diagnostic kit.

Iressa is the first molecularly targeted drug for the treatment of lung cancer in China. It was officially launched in China with the approval of the State Food and Drug Administration in 2005, opening a new era of treatment for patients with advanced non-small cell lung cancer. Iressa brings more optimized treatment options to lung cancer patients in China to improve their quality of life and has a tendency to prolong their survival. On the 6th anniversary of the listing of Iressa, Iressa was also approved as a first-line treatment for non-small cell lung cancer.

Lung cancer is the number one cancer among tumor-related death rates in China. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases.

At present, the treatment of lung cancer is still mainly surgery, radiation therapy, and drug therapy. Drug therapy for lung cancer includes chemotherapy and molecularly targeted drug therapy (common to EGFR-TKIs).

The treatment of lung cancer, especially non-small cell lung cancer, advocates an individualized treatment model. It is based on the driver gene expression status of lung cancer patients, that is, individualized treatment based on whether lung cancer patients have driver genes. Among them, epidermal growth factor receptor (EGFR) belongs to tyrosine kinase receptor, and its signal transduction pathway regulates cell growth, proliferation and differentiation. In cancer, it is found that various mutations often occur in the EGFR tyrosine kinase region. These mutations are closely related to the efficacy of tyrosine kinase inhibitors. EGFR mutation is an important cancer driver. EGFR mutation is a strong predictor of whether cancer patients are sensitive to TKI. Therefore, the detection of EGFR gene mutations can provide a basis for tumor targeted therapy. The EGFR mutation rate of lung cancer patients in China is 30% -40%.

EGFR gene mutation sites determine whether non-small cell lung cancer patients can use Iressa, Tarceva and other targeted drugs. Iressa / Trokai mutations in exons 18, 19, 20, and 21, especially the deletion of exon 19 or the mutation of exon 21, have a significant effect. It is recommended that patients with non-small cell lung cancer undergo genetic testing before using targeted drugs such as Iressa / Troca.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Cancer

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer
Bladder cancer

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer

“Nogapendekin Alfa Inbakicept-PMLN, a novel immunotherapy, shows promise in treating bladder cancer when combined with BCG therapy. This innovative approach targets specific cancer markers while leveraging the immune system’s response, enhancing the efficacy of traditional treatments like BCG. Clinical trials reveal encouraging results, indicating improved patient outcomes and potential advancements in bladder cancer management. The synergy between Nogapendekin Alfa Inbakicept-PMLN and BCG heralds a new era in bladder cancer treatment.”

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy